{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T03:35:44Z","timestamp":1772595344252,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s43440-025-00719-4","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T14:24:54Z","timestamp":1743690294000},"page":"751-760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Potential drug-drug interactions analysis in Polish pediatric hemato-oncologic unit, including acute lymphoblastic leukemia patients"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-9975","authenticated-orcid":false,"given":"Arkadiusz","family":"Adamiszak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6416-7068","authenticated-orcid":false,"given":"Julia","family":"Drobi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7598-3665","authenticated-orcid":false,"given":"Izabela","family":"Niewiadomska-Wojna\u0142owicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7239-4035","authenticated-orcid":false,"given":"Katarzyna","family":"Derwich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9938-6729","authenticated-orcid":false,"given":"Edmund","family":"Grze\u015bkowiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-5738","authenticated-orcid":false,"given":"Agnieszka","family":"Bienert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"719_CR1","doi-asserted-by":"publisher","first-page":"e26410","DOI":"10.1002\/PBC.26410","volume":"64","author":"TE Balk","year":"2017","unstructured":"Balk TE, van der Sijs IH, van Gelder T, Janssen JJB, van der Sluis IM, van Leeuwen RWF, et al. Drug\u2013drug interactions in pediatric oncology patients. Pediatr Blood Cancer. 2017;64:e26410. https:\/\/doi.org\/10.1002\/PBC.26410.","journal-title":"Pediatr Blood Cancer"},{"key":"719_CR2","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1542\/PEDS.2014-2015","volume":"135","author":"J Feinstein","year":"2015","unstructured":"Feinstein J, Dai D, Zhong W, Freedman J, Feudtner C. Potential drug-drug interactions in infant, child, and adolescent patients in children\u2019s hospitals. Pediatrics. 2015;135:e99\u2013108. https:\/\/doi.org\/10.1542\/PEDS.2014-2015.","journal-title":"Pediatrics"},{"key":"719_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1177\/1078155219882081","volume":"26","author":"B Joseph","year":"2020","unstructured":"Joseph B, Scott JX, Rajanandh MG. Surveillance of adverse drug reactions and drug-drug interactions with pediatric oncology patients in a South Indian tertiary care hospital. J Oncol Pharm Pract. 2020;26:1103\u20139. https:\/\/doi.org\/10.1177\/1078155219882081.","journal-title":"J Oncol Pharm Pract"},{"key":"719_CR4","doi-asserted-by":"publisher","first-page":"E146","DOI":"10.1097\/MPH.0000000000001346","volume":"41","author":"F Tavousi","year":"2019","unstructured":"Tavousi F, Sadeghi A, Darakhshandeh A, Moghaddas A. Potential Drug-drug interactions at a referral pediatric oncology ward in Iran: A Cross-sectional study. J Pediatr Hematol Oncol. 2019;41:E146\u201351. https:\/\/doi.org\/10.1097\/MPH.0000000000001346.","journal-title":"J Pediatr Hematol Oncol"},{"key":"719_CR5","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1007\/S11096-014-0011-1","volume":"36","author":"MA Fern\u00e1ndez de Palencia Espinosa","year":"2014","unstructured":"Fern\u00e1ndez de Palencia Espinosa MA, D\u00edaz Carrasco MS, Fuster Soler JL, Ru\u00edz Merino G, De la Rubia Nieto MA, Espuny Mir\u00f3 A. Pharmacoepidemiological study of drug-drug interactions in onco-hematological pediatric patients. Int J Clin Pharm. 2014;36:1160\u20139. https:\/\/doi.org\/10.1007\/S11096-014-0011-1.","journal-title":"Int J Clin Pharm"},{"key":"719_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(04)01528-1","volume":"5","author":"JH Beijnen","year":"2004","unstructured":"Beijnen JH, Schellens JHM. Drug interactions in oncology. Lancet Oncol. 2004;5:489\u201396. https:\/\/doi.org\/10.1016\/S1470-2045(04)01528-1.","journal-title":"Lancet Oncol"},{"key":"719_CR7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1080\/07357900601063766","volume":"24","author":"RP Riechelmann","year":"2006","unstructured":"Riechelmann RP, Saad ED. A systematic review on drug interactions in oncology. Cancer Invest. 2006;24:704\u201312. https:\/\/doi.org\/10.1080\/07357900601063766.","journal-title":"Cancer Invest"},{"key":"719_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/10781552221079786","volume":"28","author":"C Daignault","year":"2022","unstructured":"Daignault C, Sauer HE, Lindsay H, Alonzo A, Foster J. Investigating potential Drug-Drug interactions in pediatric and adolescent patients receiving chemotherapy. J Oncol Pharm Pract. 2022;28:904\u20139. https:\/\/doi.org\/10.1177\/10781552221079786.","journal-title":"J Oncol Pharm Pract"},{"key":"719_CR9","unstructured":"Drugs.com Drug Interactions Checker. https:\/\/www.drugs.com\/drug_interactions.html"},{"key":"719_CR10","doi-asserted-by":"publisher","unstructured":"Gore R, Chugh PK, Tripathi CD, Lhamo Y, Gautam S. Pediatric Off-Label and unlicensed drug use and its implications. Curr Clin Pharmacol. 2017;12. https:\/\/doi.org\/10.2174\/1574884712666170317161935.","DOI":"10.2174\/1574884712666170317161935"},{"key":"719_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00228-014-1768-9","volume":"71","author":"J Magalh\u00e3es","year":"2015","unstructured":"Magalh\u00e3es J, Teixeira Rodrigues A, Roque F, Figueiras A, Falc\u00e3o A, Herdeiro MT. Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review. Eur J Clin Pharmacol. 2015;71:1\u201313. https:\/\/doi.org\/10.1007\/S00228-014-1768-9.","journal-title":"Eur J Clin Pharmacol"},{"key":"719_CR12","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/S40262-015-0298-7","volume":"54","author":"F Rodieux","year":"2015","unstructured":"Rodieux F, Wilbaux M, van den Anker JN, Pfister M. Effect of kidney function on drug kinetics and dosing in neonates, infants, and children. Clin Pharmacokinet. 2015;54:1183\u2013204. https:\/\/doi.org\/10.1007\/S40262-015-0298-7.","journal-title":"Clin Pharmacokinet"},{"key":"719_CR13","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMRA035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental Pharmacology \u2014 Drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157\u201367. https:\/\/doi.org\/10.1056\/NEJMRA035092.","journal-title":"N Engl J Med"},{"key":"719_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/ANNUREV.NUTR.22.111401.145049","volume":"22","author":"SJ Fomon","year":"2002","unstructured":"Fomon SJ, Nelson SE. Body composition of the male and female reference infants. Annu Rev Nutr. 2002;22:1\u201317. https:\/\/doi.org\/10.1146\/ANNUREV.NUTR.22.111401.145049.","journal-title":"Annu Rev Nutr"},{"key":"719_CR15","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1111\/bcp.15168","volume":"88","author":"A Peri\u0107","year":"2022","unstructured":"Peri\u0107 A, Udilovi\u0107 A, Dobri\u0107 S, Vezmar Kova\u010devi\u0107 S. The impact of treatment choices on potential drug-drug interactions in hypertensive patients. Br J Clin Pharmacol. 2022;88:2340\u20138. https:\/\/doi.org\/10.1111\/bcp.15168.","journal-title":"Br J Clin Pharmacol"},{"key":"719_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1609\/ICWSM.V3I1.13937","volume":"3","author":"M Bastian","year":"2009","unstructured":"Bastian M, Heymann S, Jacomy M. Gephi: an open source software for exploring and manipulating networks. Proc Int AAAI Conf Web Social Media. 2009;3:361\u20132. https:\/\/doi.org\/10.1609\/ICWSM.V3I1.13937.","journal-title":"Proc Int AAAI Conf Web Social Media"},{"key":"719_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11096-011-9600-4","volume":"34","author":"HW Tuffaha","year":"2012","unstructured":"Tuffaha HW, Abdelhadi O, Omar SA. Clinical pharmacy services in the outpatient pediatric oncology clinics at a comprehensive cancer center. Int J Clin Pharm. 2012;34:27\u201331. https:\/\/doi.org\/10.1007\/s11096-011-9600-4.","journal-title":"Int J Clin Pharm"},{"key":"719_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/1078155220934167","volume":"27","author":"K Ali","year":"2021","unstructured":"Ali K, Al-Quteimat O, Naseem R, Malhi SM, wajdi M, Jahan N, et al. Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology\u2013oncology and transplant clinic: assessment and significance. J Oncol Pharm Pract. 2021;27:815\u201320. https:\/\/doi.org\/10.1177\/1078155220934167.","journal-title":"J Oncol Pharm Pract"},{"issue":"Suppl 1","key":"719_CR19","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.1002\/JCPH.1881","volume":"61","author":"D Gonzalez","year":"2021","unstructured":"Gonzalez D, Sinha J. Pediatric Drug-Drug interaction evaluation: drug, patient population, A.nd methodological considerations. J Clin Pharmacol. 2021;61(Suppl 1):S175\u201387. https:\/\/doi.org\/10.1002\/JCPH.1881.","journal-title":"J Clin Pharmacol"},{"key":"719_CR20","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1097\/PCC.0000000000000684","volume":"17","author":"D Dai","year":"2016","unstructured":"Dai D, Feinstein JA, Morrison W, Zuppa AF, Feudtner C. Epidemiology of polypharmacy and potential Drug-Drug interactions among pediatric patients in intensive care units of U.S. Children\u2019s hospitals. Pediatr Crit Care Med. 2016;17:e218. https:\/\/doi.org\/10.1097\/PCC.0000000000000684.","journal-title":"Pediatr Crit Care Med"},{"key":"719_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/S00228-016-2193-Z","volume":"73","author":"M Herr","year":"2017","unstructured":"Herr M, Grondin H, Sanchez S, Armaingaud D, Blochet C, Vial A, et al. Polypharmacy and potentially inappropriate medications: a cross-sectional analysis among 451 nursing homes in France. Eur J Clin Pharmacol. 2017;73:601\u20138. https:\/\/doi.org\/10.1007\/S00228-016-2193-Z.","journal-title":"Eur J Clin Pharmacol"},{"key":"719_CR22","doi-asserted-by":"publisher","unstructured":"Guillot J, Maumus-Robert S, Bezin J, Polypharmacy. A general review of definitions, descriptions and determinants. Therapie. 2020;75. https:\/\/doi.org\/10.1016\/J.THERAP.2019.10.001.","DOI":"10.1016\/J.THERAP.2019.10.001"},{"key":"719_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s11096-021-01303-5","volume":"44","author":"B Guidi","year":"2022","unstructured":"Guidi B, Parziale A, Nocco L, Maiese A, La Russa R, Di Paolo M, et al. Regulating pediatric off-label uses of medicines in the EU and USA: challenges and potential solutions. Int J Clin Pharm. 2022;44:264\u20139. https:\/\/doi.org\/10.1007\/s11096-021-01303-5.","journal-title":"Int J Clin Pharm"},{"key":"719_CR24","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/annonc\/mdv029","volume":"26","author":"RWF van Leeuwen","year":"2015","unstructured":"van Leeuwen RWF, Jansman FGA, van den Bemt PMLA, de Man F, Piran F, Vincenten I, et al. Drug\u2013drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol. 2015;26:992\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdv029.","journal-title":"Ann Oncol"},{"key":"719_CR25","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.3390\/jcm12144637","volume":"12","author":"B Sienkiewicz-Oleszkiewicz","year":"2023","unstructured":"Sienkiewicz-Oleszkiewicz B, Salamonowicz-Bodzioch M, S\u0142onka J, Ka\u0142wak K. Antifungal Drug-Drug interactions with commonly used pharmaceutics in European pediatric patients with acute lymphoblastic leukemia. J Clin Med. 2023;12:4637. https:\/\/doi.org\/10.3390\/jcm12144637.","journal-title":"J Clin Med"},{"key":"719_CR26","doi-asserted-by":"publisher","first-page":"1244151","DOI":"10.3389\/fphar.2023.1244151","volume":"14","author":"K Urba\u0144czyk","year":"2023","unstructured":"Urba\u0144czyk K, Guntschnig S, Antoniadis V, Falamic S, Kovacevic T, Kurczewska-Michalak M, et al. Recommendations for wider adoption of clinical pharmacy in central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes. Front Pharmacol. 2023;14:1244151. https:\/\/doi.org\/10.3389\/fphar.2023.1244151.","journal-title":"Front Pharmacol"},{"key":"719_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/ijpp\/riac037","volume":"30","author":"M Solano","year":"2022","unstructured":"Solano M, Jeannin M, Anxionnat R, Vardanega J, Ridley A, Amsallem D, et al. Impact of pharmacist medication review for paediatric patients: an observational study. Int J Pharm Pract. 2022;30:420\u20136. https:\/\/doi.org\/10.1093\/ijpp\/riac037.","journal-title":"Int J Pharm Pract"},{"key":"719_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/J.JGO.2020.07.010","volume":"12","author":"C Choukroun","year":"2021","unstructured":"Choukroun C, Leguelinel-Blache G, Roux-Marson C, Jamet C, Martin-Allier A, Kinowski JM, et al. Impact of a pharmacist and geriatrician medication review on drug-related problems in older outpatients with cancer. J Geriatr Oncol. 2021;12:57\u201363. https:\/\/doi.org\/10.1016\/J.JGO.2020.07.010.","journal-title":"J Geriatr Oncol"},{"key":"719_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/FPC.0000000000000432","volume":"31","author":"I Radulovic","year":"2021","unstructured":"Radulovic I, Dogan B, Dohna-Schwake C, Sch\u00fcndeln MM, Siffert W, M\u00f6hlendick B. NAT2 polymorphisms as a cause of metamizole-induced agranulocytosis. Pharmacogenet Genomics. 2021;31:140\u20133. https:\/\/doi.org\/10.1097\/FPC.0000000000000432.","journal-title":"Pharmacogenet Genomics"},{"key":"719_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.bcp.2014.09.005","volume":"92","author":"C Mart\u00ednez","year":"2014","unstructured":"Mart\u00ednez C, Andreu I, Amo G, Miranda MA, Esguevillas G, Torres MJ, et al. Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole. Biochem Pharmacol. 2014;92:457\u201366. https:\/\/doi.org\/10.1016\/j.bcp.2014.09.005.","journal-title":"Biochem Pharmacol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00719-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00719-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00719-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T13:10:09Z","timestamp":1747055409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00719-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00719-4","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}